Multiple The 15th Annual Johns Hopkins Sclerosis Symposium Series

Access Activity

Overview / Abstract:

Program Overview

Although there is no medication that can fully prevent or reverse the neurologic deterioration associated with multiple sclerosis (MS), the use of disease-modifying therapy (DMT) is widely recommended to favorably impact prognosis and reduce disability. The number of DMTs now approved by the US Food and Drug Administration has grown substantially, resulting in more options for patients, but also increasing the complexity of starting, stopping, and switching treatments for healthcare providers (HCPs), who must consider the different modes of administration (injectable, oral, or intravenous), pharmacologic profiles, and benefit-risk profiles, in the context of individual- and disease-specific factors. Thus, although it is encouraging to have many options that have been shown to reduce the frequency and severity of relapses, to limit the development of new lesion activity, and to delay the progression of disability, many clinicians struggle to find the time and skills needed to appraise the large body of available safety and efficacy data for these DMTs and to translate that information into optimal treatment choices for their patients. Furthermore, suboptimal management of the whole patient (ie, focusing on the symptoms or relapses while ignoring other impacts and burdens on the patient), and the lack of shared decision-making may result in the selection of a treatment approach that is out of sync with an individual’s values, preferences, and therapy goals.

Management of MS as a chronic, multifaceted disease requires multidisciplinary care from a collaborative team of specialty and primary care HCPs. This opportunity seeks to facilitate this team-based care by providing education in a format that addresses both the unique and common educational needs of specialty and primary care HCPs, provides a forum in which to share the latest evidence-based information, and explores best practices for MS care in a primary care setting, specialty setting, and collaborative setting.

Learning Objectives

Upon completion of this activity, participants should be able to:

Facilitate strategies that support the early recognition and treatment of multiple sclerosis
Assess clinical trial and real-world efficacy and safety data for DMTs recently approved for relapsing and progressive forms of MS 
Propose effective shared decision making and collaborative care strategies to optimize MS management plans 


Nov 17, 2022


Nursing CNE, Physician CME



Credits / Hours

1.5 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty


Scott Newsome, DO, MSCS, FAAN, FANA (Chairperson)
Associate Professor of Neurology
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Co-Director, Johns Hopkins Neuroimmunology Clinical Fellowship Program
Member, Miller-Coulson Academy of Clinical Excellence
Johns Hopkins Hospital
Division of Neuroimmunology and Neuroinfectious Diseases
Baltimore, Maryland

Lisa Fox, PA-C
Associate Director
Department of Neurology
Neurology Outpatients Infusion Center
Baltimore, Maryland

Jiwon Oh, MD, PhD, FRCPC
Staff Neurologist
Medical Director, of the Barl Multiple Sclerosis Program
St. Michael’s HospitalUniversity of Toronto
Toronto, Canada

Sponsors / Supporters / Grant Providers

Biogen and Bristol-Meyers Squibb.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Sclerosis Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map